CDC to monitor novel virus after China infection reports

According to Chuang, all but nine of the 35 cases in China were infected with LayV only, with symptoms such as fever, fatigue, and coughing.
 
However, no deaths have been reported due to LayV so far but this situation requires further monitoring, he said.
 
The virus, discovery of which was announced in a letter to the editor published in the New England Journal of Medicine on Aug. 4, has been predominantly detected in shrews.
 
According to researchers, it is not yet known if the virus can be transmitted from human to human.
 
LayV belongs to the Paramyxoviride family, which, according to the article on NEJM, can "infect humans and cause fatal disease."

A shrew. The mammal species is suspected to be a carrier of the virus. Photo by W.A. Djatmiko, CC BY-SA 3.0, via Wikimedia Commons

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern. Data from the Phase 2/3 trial found that a booster dose of both Omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1 as compared to the companies’ current COVID-19 vaccine. The robust immune response was seen across two investigational dose levels, 30 µg and 60 µg. [...]

June 29 (Reuters) - Germany's BioNTech (22UAy.DE), Pfizer's (PFE.N) partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.
 
Their experimental work on shots that go beyond the current approach include T-cell-enhancing shots, designed to primarily protect against severe disease if the virus becomes more dangerous, and pan-coronavirus shots that protect against the broader family of viruses and its mutations.
 
In presentation slides posted on BioNTech's website for its investor day, the German biotech firm said its aim was to "provide durable variant protection".

NEW YORK and MAINZ, Germany, July 27, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant. The enhanced spike protein encoded from the mRNAs in BNT162b5 has been modified with the aim of increasing the magnitude and breadth of the immune response that could better protect against COVID-19.
 
This is the first of multiple vaccine candidates with an enhanced design which the companies plan to evaluate as part of a long-term scientific COVID-19 vaccine strategy to potentially generate more robust, longer-lasting, and broader immune responses against SARS-CoV-2 infections and associated COVID-19.

The two companies have begun a Phase II study on an ‘enhanced’ version of their mRNA vaccine against COVID-19.
The vaccine candidate, known as BNT162b5, is a bivalent vaccine that contains enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain and for an Omicron variant.
 
In the announcement, the companies explained that by ‘enhanced’, it is meant that BNT162b5 the spike protein encoded from the mRNAs has been modified with the aim of increasing the magnitude and breadth of the immune response in recipients, potentially better protecting against COVID-19.
 
Pfizer and BioNTech have previously advanced an Omicron-adapted vaccine candidate, with the partners posting results in late June that this monovalent vaccine resulted in a ‘substantially higher’ immune response compared with the existing vaccine.
 
However, the companies look set to pursue vaccine candidates with this enhanced, bivalent design, with an eye on providing a longer-term strategy against COVID-19. BNT162b5 represents the “first of multiple vaccine candidates” designed in the same manner, the companies stated.
 
In terms of the trial, BNT162b5 will be tested in the US in approximately 200 recipients aged between 18 and 55 who have received one booster dose of a COVID-19 vaccine, at least 90 days prior to their first study visit.

Bonjour je suis vraiment écœurée mais ils ne sont donc pas fatigués ils ne lâchent rien nous non plus, nous allons les balayés ras le bol
Pourtant c est reconnu officiellement sauf en France que l ivermectine et hydroxyde cloroquine soignent

Bonjour,
Tout notre soutien au Professeur Peronne, un grand homme humble, un héros au grand coeur qui s’est battu pour nous et pour la vérité, merci pour tout !!!
Voici le clip d’une chanson engagée que j ai écrite en décembre 2022 sur la crise du covid qui dénonce la dictature sanitaire, la propagande médiatique, le contrôle numérique etc.
Nous avons tous travaillé bénévolement pour la réalisation de ce projet, réunis par l’envie commune de faire quelque chose pour protester, avec nos modestes moyens.
Fraîchement sortie le 14 juillet 2022,
« Faut s’réveiller » est à découvrir et à partager:

https://youtu.be/w1E3F2aT_V8

Merci de transférer la chanson au Professeur Peronne qui est pour nous une source de réconfort et d »inspiration depuis plus de deux ans .
Un grand à vous de prendre sa défense et pour cette initiative!